Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (cellbank.brc@riken.jp).
4590
Arai S, Minjares C, Nagafuchi S, Miyazaki T.
Improved experimental procedures for achieving efficient germ line transmission of nonobese diabetic (NOD)-derived embryonic stem cells.Exp Diabesity Res
2004
5(3):219-26
PubMed ID: 15512790
DOI: 10.1080/15438600490486877
4589
Nagafuchi S, Katsuta H, Kogawa K, Akashi T, Kondo S, Sakai Y, Tsukiyama T, Kitamura D, Niho Y, Watanabe T.
Establishment of an embryonic stem (ES) cell line derived from a non-obese diabetic (NOD) mouse: in vivo differentiation into lymphocytes and potential for germ line transmission.FEBS Lett
1999
455(1-2):101-4.
PubMed ID: 10428481
DOI: 10.1016/s0014-5793(99)00801-7
4591
Ikeda T, Hirata S, Takamatsu K, Haruta M, Tsukamoto H, Ito T, Uchino M, Ando Y, Nagafuchi S, Nishimura Y, Senju S.
Suppression of Th1-mediated autoimmunity by embryonic stem cell-derived dendritic cells.PLoS One
2014
9(12):e115198
PubMed ID: 25522369
DOI: 10.1371/journal.pone.0115198